{"id":"NCT01816139","sponsor":"Warner Chilcott","briefTitle":"Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women","officialTitle":"A Randomized, Multicenter, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of WC3011 in Postmenopausal Women","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-31","primaryCompletion":"2013-11-19","completion":"2013-11-19","firstPosted":"2013-03-21","resultsPosted":"2022-05-09","lastUpdate":"2022-05-09"},"enrollment":576,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Vulvovaginal Atrophy"],"interventions":[{"type":"DRUG","name":"Vehicle","otherNames":[]},{"type":"DRUG","name":"WC3011 Estradiol Vaginal Cream","otherNames":[]}],"arms":[{"label":"Vehicle (2 Times/Week)","type":"EXPERIMENTAL"},{"label":"WC3011 Estradiol Vaginal Cream (2 Times/Week)","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to compare the efficacy of WC3011 with placebo vaginal gel in postmenopausal women for the relief of vaginal dryness caused by vaginal atrophy as measured by self-assessment, vaginal pH and vaginal smear.","primaryOutcome":{"measure":"Change From Baseline in Participant's Self-Assessment of Severity of Vaginal Dryness to Final Assessment","timeFrame":"Baseline (Day 0) to final assessment (Up to Week 12)","effectByArm":[{"arm":"Vehicle (2 Times/Week)","deltaMin":2.5,"sd":0.5},{"arm":"WC3011 Estradiol Vaginal Cream (2 Times/Week)","deltaMin":2.5,"sd":0.5}],"pValues":[]},"eligibility":{"minAge":"35 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":48,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":287},"commonTop":["Urinary tract infection","Application site pain","Vulvovaginal mycotic infection"]}}